隆基股份(601012.SH)與成都通威簽訂129.98億元的硅片銷售框架合同
格隆匯1月22日丨隆基股份(601012.SH)公佈,根據公司戰略規劃與經營計劃,公司與通威太陽能(成都)有限公司(“成都通威”)於2020年1月22日簽訂了硅片銷售框架合同,就2020年-2022年公司向通威供應單晶硅片事宜達成合作。
根據PV InfoLink於2020年1月15日公告的光伏產品市場平均價格測算(P型單晶硅片-180um3.06元/片),預估此次合同總金額約129.98億元(不含税),佔公司2018年度經審計營業收入的約59.12%,該合同屬於特別重大銷售合同,該測算不構成價格或業績承諾。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.